These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7638083)

  • 1. Nuclear morphometry is of independent prognostic value only in T1 prostatic adenocarcinomas.
    Vesalainen S; Lipponen P; Talja M; Kasurinen J; Syrjänen K
    Prostate; 1995 Aug; 27(2):110-7. PubMed ID: 7638083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proliferating cell nuclear antigen and p53 expression as prognostic factors in T1-2M0 prostatic adenocarcinoma.
    Vesalainen SL; Lipponen PK; Talja MT; Alhava EM; Syrjänen KJ
    Int J Cancer; 1994 Jul; 58(2):303-8. PubMed ID: 7913085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical parameters as prognostic factors in prostatic adenocarcinoma.
    Vesalainen S; Lipponen P; Talja M; Syrjänen K
    Acta Oncol; 1995; 34(1):53-9. PubMed ID: 7865237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression and survival in prostatic adenocarcinoma: a comparison of clinical stage, Gleason grade, S-phase fraction and DNA ploidy.
    Vesalainen S; Nordling S; Lipponen P; Talja M; Syrjänen K
    Br J Cancer; 1994 Aug; 70(2):309-14. PubMed ID: 8054280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitotic activity and prognosis in prostatic adenocarcinoma.
    Vesalainen S; Lipponen P; Talja M; Syrjänen K
    Prostate; 1995 Feb; 26(2):80-6. PubMed ID: 7855001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of histoquantitative measurements in prognostic assessment of renal adenocarcinoma.
    Eskelinen M; Lipponen P; Aitto-Oja L; Hall O; Syrjänen K
    Int J Cancer; 1993 Oct; 55(4):547-54. PubMed ID: 8406980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prognostic score for prostatic adenocarcinoma based on clinical, histological, biochemical and cytometric data from the primary tumour.
    Lipponen P; Vesalainen S; Kasurinen J; Ala-Opas M; Syrjänen K
    Anticancer Res; 1996; 16(4A):2095-100. PubMed ID: 8712749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic value of DNA ploidy and nuclear morphometry in metastatic prostate cancer].
    Martínez Jabaloyas JM; Jiménez Sánchez A; Ruiz Cerdá JL; Sanz Chinesta S; Sempere A; Jiménez Cruz JF
    Actas Urol Esp; 2004 Apr; 28(4):298-307. PubMed ID: 15248401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of nuclear morphometry on needle biopsy from patients with prostate cancer: is volume-weighted mean nuclear volume superior to other morphometric parameters?
    Zhang YH; Kanamaru H; Oyama N; Miwa Y; Suzuki Y; Akino H; Noriki S; Okada K
    Urology; 2000 Mar; 55(3):377-81. PubMed ID: 10699614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor vascularity and basement membrane structure as prognostic factors in T1-2MO prostatic adenocarcinoma.
    Vesalainen S; Lipponen P; Talja M; Alhava E; Syrjänen K
    Anticancer Res; 1994; 14(2B):709-14. PubMed ID: 8010731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors in prostatic adenocarcinoma assessed by means of quantitative histology.
    Eskelinen M; Lipponen P; Majapuro R; Syrjänen K
    Eur Urol; 1991; 19(4):274-8. PubMed ID: 1915532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of nuclear morphometry, gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer.
    Partin AW; Steinberg GD; Pitcock RV; Wu L; Piantadosi S; Coffey DS; Epstein JI
    Cancer; 1992 Jul; 70(1):161-8. PubMed ID: 1606538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of DNA ploidy and nuclear morphometry in prostate cancer treated with androgen deprivation.
    Martínez-Jabaloyas JM; Ruiz-Cerdá JL; Hernández M; Jiménez A; Jiménez-Cruz F
    Urology; 2002 May; 59(5):715-20. PubMed ID: 11992846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of classic and quantitative prognostic factors in colorectal cancer.
    Ropponen K; Eskelinen M; Kosma VM; Lipponen P; Paakkinen P; Alhava E
    Anticancer Res; 1996; 16(6B):3875-82. PubMed ID: 9042274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear morphometry predicts disease-free interval for clinically localized adenocarcinoma of the prostate treated with definitive radiation therapy.
    Hurwitz MD; DeWeese TL; Zinreich ES; Epstein JI; Partin AW
    Int J Cancer; 1999 Dec; 84(6):594-7. PubMed ID: 10567904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of histologic grading in patients with prostate carcinoma who are assessed by the Gleason and World Health Organization grading systems in needle biopsies obtained prior to radiotherapy.
    Lilleby W; Torlakovic G; Torlakovic E; Skovlund E; Fosså SD
    Cancer; 2001 Jul; 92(2):311-9. PubMed ID: 11466684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance and outcome of nuclear anaplasia and mitotic index in prostatic adenocarcinomas.
    Kır G; Sarbay BC; Gumus E
    Urol Oncol; 2016 Oct; 34(10):430.e9-430.e16. PubMed ID: 27264167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ability to predict biochemical progression using Gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei.
    Veltri RW; Miller MC; Partin AW; Coffey DS; Epstein JI
    Urology; 1996 Nov; 48(5):685-91. PubMed ID: 8911509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear morphometry in histological specimens of canine prostate cancer: Correlation with histological subtypes, Gleason score, methods of collection and survival time.
    Di Donato G; Laufer-Amorim R; Palmieri C
    Res Vet Sci; 2017 Oct; 114():212-217. PubMed ID: 28502900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereologically measured nuclear volume in comparison to two-dimensional nuclear morphometry, mitotic index and flow cytometry in predicting disease outcome in bladder cancer.
    Lipponen PK
    Anticancer Res; 1993; 13(2):529-32. PubMed ID: 8517668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.